Demonstrated Safety Profile in DR

The most common adverse reactions (5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain,
cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.1

VISTA and VIVID: Most common
adverse reactions (1%)1

1 / 3
2 / 3
3 / 3
3 / 3

Less common adverse reactions reported in <1% of the patients treated with EYLEA were
hypersensitivity, retinal detachment, retinal tear, corneal edema, and injection site hemorrhage.1

VISTA and VIVID long-term safety: Most common adverse reactions2

1 / 3
2 / 3

DR phase 3 PANORAMA safety

  • Safety data observed in 269 patients with NPDR through Year 1 (Week 52) in the PANORAMA trial were consistent with those seen in the
    phase 3 VIVID and VISTA trials1
  • No new safety signals were identified through Year 2 in the PANORAMA trial compared with the known safety profile of EYLEA in the DR population3

NPDR, nonproliferative diabetic retinopathy; SAE, serious adverse event.

Find out more about all
EYLEA indications

Support for the reimbursement process.
Reimbursement Support

Get information about navigating the reimbursement process. Find enrollment forms, learn about PA assistance, and more.

Product support for EYLEA® (aflibercept) Injection.
Product Support

Find complete product support—
guiding you through
orders, returns, and more.

EYLEA news, events, and more.
Resources

Get the information you
and your patients need
about EYLEA.

See More Important Safety Information and Indications
  • CONTRAINDICATIONS: EYLEA is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection 2 mg (0.05 mL) is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

References
  1. EYLEA® (aflibercept) Injection full U.S. Prescribing Information. Regeneron Pharmaceuticals, Inc. March 2021
  2. Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123(11):2376-2385. doi:10.1016/j.ophtha.2016.07.032
  3. Wykoff CC. Intravitreal aflibercept for moderately severe to severe non-proliferative diabetic retinopathy (NPDR): 2-year outcomes of the phase 3 PANORAMA study. Data presented at: Angiogenesis, Exudation, and Degeneration Annual Meeting; February 8, 2020; Miami, FL.